Citius Oncology (CTOR) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $0.75, -4.85% vs the prior close of $0.78.
- Volume 11.00K shares, 0.1x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
CTOR slides 4.8% to $0.75, a 1-month low, 4 down days in a row. Closed at $0.75, -4.85% vs the prior close of $0.78. Day range $0.75–$0.77, opened at $0.76.
CTOR daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — CTOR slides 4.8% to $0.75, a 1-month low, 4 down days in a row
- Closed at $0.75, -4.85% vs the prior close of $0.78. Day range $0.75–$0.77, opened at $0.76.
- Volume was 11.00K shares, 0.1x its 50-day average of 112.49K — lighter than usual.
- Price is -13.9% vs its 50-day average ($0.87) and -13.3% vs its 200-day average ($0.86).
- 52-week range $0.49–$2.25; today's close sits at 14% of that range, 66.8% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — CTOR dips 1.0% to $0.78, a 1-month low, 3 down days in a row
- Closed at $0.78, -1.01% vs the prior close of $0.79. Day range $0.75–$0.81, opened at $0.81.
- Volume was 27.60K shares, 0.2x its 50-day average of 113.42K — lighter than usual.
- Price is -9.6% vs its 50-day average ($0.87) and -9.0% vs its 200-day average ($0.86).
- 52-week range $0.49–$2.25; today's close sits at 17% of that range, 65.2% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — CTOR dips 2.6% to $0.79, a 1-month low
- Closed at $0.79, -2.58% vs the prior close of $0.81. Day range $0.74–$0.84, opened at $0.80.
- Volume was 96.70K shares, 0.9x its 50-day average of 113.38K.
- Price is -8.4% vs its 50-day average ($0.86) and -8.3% vs its 200-day average ($0.86).
- 52-week range $0.49–$2.25; today's close sits at 17% of that range, 64.8% below the 52-week high.
Oct 12, 2026 — CTOR slides 3.2% to $0.81, a 1-month low
- Closed at $0.81, -3.21% vs the prior close of $0.84. Day range $0.78–$0.86, opened at $0.86.
- Volume was 67.90K shares, 0.6x its 50-day average of 112.82K.
- Price is -5.6% vs its 50-day average ($0.86) and -6.1% vs its 200-day average ($0.87).
- 52-week range $0.49–$2.25; today's close sits at 18% of that range, 63.9% below the 52-week high.
Oct 9, 2026 — CTOR rises 0.6% to $0.84
- Closed at $0.84, +0.60% vs the prior close of $0.83. Day range $0.80–$0.88, opened at $0.84.
- Volume was 71.00K shares, 0.6x its 50-day average of 111.96K.
- Price is -2.0% vs its 50-day average ($0.86) and -3.2% vs its 200-day average ($0.87).
- 52-week range $0.49–$2.25; today's close sits at 20% of that range, 62.7% below the 52-week high.
Oct 8, 2026 — CTOR dips 1.9% to $0.83, a 1-month low
- Closed at $0.83, -1.88% vs the prior close of $0.85. Day range $0.82–$0.87, opened at $0.87.
- Volume was 56.40K shares, 0.5x its 50-day average of 111.05K — lighter than usual.
- Price is -2.0% vs its 50-day average ($0.85) and -4.0% vs its 200-day average ($0.87).
- 52-week range $0.49–$2.25; today's close sits at 20% of that range, 62.9% below the 52-week high.
Oct 7, 2026 — CTOR ends flat (+0.1%) to $0.85
- Closed at $0.85, +0.12% vs the prior close of $0.85. Day range $0.85–$0.90, opened at $0.85.
- Volume was 105.50K shares, 1.0x its 50-day average of 109.59K.
- Price is +0.6% vs its 50-day average ($0.85) and -2.5% vs its 200-day average ($0.87).
- 52-week range $0.49–$2.25; today's close sits at 20% of that range, 62.2% below the 52-week high.
Oct 6, 2026 — CTOR dips 2.7% to $0.85, a 1-month low, 5 down days in a row
- Closed at $0.85, -2.75% vs the prior close of $0.87. Day range $0.81–$0.92, opened at $0.86.
- Volume was 109.80K shares, 1.0x its 50-day average of 108.05K.
- Price is +1.3% vs its 50-day average ($0.84) and -2.8% vs its 200-day average ($0.87).
- 52-week range $0.49–$2.25; today's close sits at 20% of that range, 62.2% below the 52-week high.
- That makes 5 straight losses.
Oct 5, 2026 — CTOR slides 8.0% to $0.87, 4 down days in a row
- Closed at $0.87, -8.00% vs the prior close of $0.95. Day range $0.86–$0.93, opened at $0.93.
- Volume was 85.50K shares, 0.8x its 50-day average of 107.45K.
- Price is +4.8% vs its 50-day average ($0.83) and -0.2% vs its 200-day average ($0.88).
- 52-week range $0.49–$2.25; today's close sits at 22% of that range, 61.2% below the 52-week high.
- That makes 4 straight losses.
Oct 2, 2026 — CTOR slides 3.1% to $0.95 on 2.0x normal volume
- Closed at $0.95, -3.06% vs the prior close of $0.98. Day range $0.91–$1.05, opened at $1.00.
- Volume was 208.40K shares, 2.0x its 50-day average of 104.32K — unusually heavy trading.
- Price is +14.8% vs its 50-day average ($0.83) and +8.4% vs its 200-day average ($0.88).
- 52-week range $0.49–$2.25; today's close sits at 26% of that range, 57.8% below the 52-week high.
- That makes 3 straight losses.
CTOR latest news & SEC filings
Every SEC filing by or about CTOR in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Aug 26, 2026 · Form ARS — Annual report to shareholders
Annual report to shareholders
Aug 26, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Aug 14, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 14, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 14, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $1.49M
- Net income: -$8.92M (prior year -$5.37M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.08 (prior year -$0.08) ( vs Jun 30, 2025)
Aug 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 5, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade CTOR
- Last results release: Aug 14, 2026 (8-K Item 2.02). Previous ones: May 15, 2026, Feb 13, 2026, Dec 23, 2025. Based on that rhythm, the next report is likely around Nov 13, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.54% (largest 11.8%). That is a volatile stock.
- Liquidity: about 99.75K shares (≈$74.41K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.75 vs a range of $0.49–$2.25 (14% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Sep 29, 2026; 10-Q Aug 14, 2026; 8-K Aug 14, 2026.
- Share count: 92.98M shares outstanding (Aug 13, 2026), +18.6% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
CTOR market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 0.76 | 0.77 | 0.75 | 0.75 | 11.00K |
| Oct 14, 2026 | 0.81 | 0.81 | 0.75 | 0.78 | 27.60K |
| Oct 13, 2026 | 0.80 | 0.84 | 0.74 | 0.79 | 96.70K |
| Oct 12, 2026 | 0.86 | 0.86 | 0.78 | 0.81 | 67.90K |
| Oct 9, 2026 | 0.84 | 0.88 | 0.80 | 0.84 | 71.00K |
| Oct 8, 2026 | 0.87 | 0.87 | 0.82 | 0.83 | 56.40K |
| Oct 7, 2026 | 0.85 | 0.90 | 0.85 | 0.85 | 105.50K |
| Oct 6, 2026 | 0.86 | 0.92 | 0.81 | 0.85 | 109.80K |
| Oct 5, 2026 | 0.93 | 0.93 | 0.86 | 0.87 | 85.50K |
| Oct 2, 2026 | 1.00 | 1.05 | 0.91 | 0.95 | 208.40K |
| Oct 1, 2026 | 1.07 | 1.07 | 0.94 | 0.98 | 99.60K |
| Sep 30, 2026 | 1.09 | 1.09 | 1.00 | 1.01 | 96.70K |
| Sep 29, 2026 | 1.02 | 1.13 | 1.00 | 1.05 | 186.00K |
| Sep 28, 2026 | 1.04 | 1.08 | 1.02 | 1.03 | 43.60K |
| Sep 25, 2026 | 1.07 | 1.07 | 1.02 | 1.05 | 26.70K |
| Sep 24, 2026 | 1.03 | 1.08 | 1.01 | 1.05 | 40.70K |
| Sep 23, 2026 | 1.05 | 1.07 | 0.99 | 1.01 | 55.80K |
| Sep 22, 2026 | 1.00 | 1.12 | 1.00 | 1.07 | 117.00K |
| Sep 21, 2026 | 1.15 | 1.15 | 1.03 | 1.04 | 152.20K |
| Sep 18, 2026 | 1.05 | 1.15 | 1.01 | 1.14 | 336.90K |
About Citius Oncology
Citius Oncology (CTOR) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in CRANFORD, NJ. State of incorporation: DE. Fiscal year ends September 30. SEC CIK 1851484.
CTOR board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Suren G Dutia | Director | Dec 22, 2025 |
| Myron Z Holubiak | Secretary | Dec 22, 2025 |
| Eugene Myron Holuka | Director | Dec 22, 2025 |
| Dennis M Mcgrath | Director | Dec 22, 2025 |
| Joel David Mayersohn | Director | Dec 22, 2025 |
| Leonard L Mazur | Chief Executive Officer | Dec 22, 2025 |
| Jonathan Peri | Director | Aug 14, 2026 |
| Robert Joseph Smith | Director | Dec 22, 2025 |
| Carol Webb | Director | Dec 22, 2025 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Jaime Bartushak | Chief Financial Officer | Dec 22, 2025 |
| Myron Czuczman | Chief Medical Officer | Dec 22, 2025 |
| Myron Z Holubiak | Secretary | Dec 22, 2025 |
| Leonard L Mazur | Chief Executive Officer | Dec 22, 2025 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
CTOR financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Sep 30, 2025 | — | $-24.76M | -0.34 | $-5.49M |
| Sep 30, 2024 | — | $-21.15M | -0.31 | $126.35K |
| Dec 31, 2023 | — | $2.42M | 0.27 | $-601.30K |
| Sep 30, 2023 | — | $-12.70M | -0.19 | — |
| Dec 31, 2022 | — | $380.81K | 0.12 | $-47.97K |
Latest balance sheet: total assets $112.09M, total liabilities $71.71M, cash $16.56M (as of Jun 30, 2026).
CTOR earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 14, 2026 | 8-K Item 2.02 (results) | $0.91 |
| May 15, 2026 | 8-K Item 2.02 (results) | $0.96 |
| Feb 13, 2026 | 8-K Item 2.02 (results) | $1.22 |
| Dec 23, 2025 | 8-K Item 2.02 (results) | $1.27 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $1.69 |
| May 14, 2025 | 8-K Item 2.02 (results) | $0.89 |
| Dec 27, 2024 | 8-K Item 2.02 (results) | $1.04 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on CTOR
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.